Möchten Sie immer auf dem neuesten Stand bleiben?

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to ReSTART

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT®

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Alpha Tau Announces New Pancreatic Cancer Data at ASCO 2026, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxan